Logo video2dn
  • Сохранить видео с ютуба
  • Категории
    • Музыка
    • Кино и Анимация
    • Автомобили
    • Животные
    • Спорт
    • Путешествия
    • Игры
    • Люди и Блоги
    • Юмор
    • Развлечения
    • Новости и Политика
    • Howto и Стиль
    • Diy своими руками
    • Образование
    • Наука и Технологии
    • Некоммерческие Организации
  • О сайте

Скачать или смотреть DOES CAGRISEMA BEAT ZEPBOUND? 2026 LAUNCH!

  • DOWNSIZED
  • 2025-12-19
  • 6169
DOES CAGRISEMA BEAT ZEPBOUND? 2026 LAUNCH!
Cagrisemanovo nordiskcagrisema: new weigh-loss drug
  • ok logo

Скачать DOES CAGRISEMA BEAT ZEPBOUND? 2026 LAUNCH! бесплатно в качестве 4к (2к / 1080p)

У нас вы можете скачать бесплатно DOES CAGRISEMA BEAT ZEPBOUND? 2026 LAUNCH! или посмотреть видео с ютуба в максимальном доступном качестве.

Для скачивания выберите вариант из формы ниже:

  • Информация по загрузке:

Cкачать музыку DOES CAGRISEMA BEAT ZEPBOUND? 2026 LAUNCH! бесплатно в формате MP3:

Если иконки загрузки не отобразились, ПОЖАЛУЙСТА, НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если у вас возникли трудности с загрузкой, пожалуйста, свяжитесь с нами по контактам, указанным в нижней части страницы.
Спасибо за использование сервиса video2dn.com

Описание к видео DOES CAGRISEMA BEAT ZEPBOUND? 2026 LAUNCH!

Novo Nordisk has officially submitted its next-generation obesity drug, CagriSema, to the FDA — and the data behind that filing is turning heads.

In Phase 3 trials, CagriSema delivered 20% to 23% average weight loss, with many patients losing 50 pounds or more over 68 weeks. If approved, the drug could reach the market in 2026, adding a powerful new option to the rapidly evolving obesity treatment landscape.

CagriSema is a once-weekly injectable that combines semaglutide, the GLP-1 already used in Wegovy and Ozempic, with cagrilintide, an amylin analogue designed to target appetite and satiety through a different biological pathway. That combination may help patients who respond slowly or plateau on GLP-1 therapy alone.

In this video, Christopher Durham breaks down:

What Novo actually submitted to the FDA

The full Phase 3 REDEFINE trial results and what the numbers really mean
How CagriSema compares to existing GLP-1 medications, including Zepbound and Mounjaro
Why adding an amylin pathway could expand treatment options for patients
What this FDA submission signals for pricing, access, and competition heading into 2026

This is not just a story about one drug. It’s about where obesity medicine is heading next — and whether increased competition will finally improve affordability and access for patients who need long-term treatment.
+++++++++++++++++++++++++++++++++++++++

Me Again Iphone GLP-1 App: https://apps.apple.com/us/app/meagain...

Get your Hume BodyPod today and use our exclusive Downsized code for an extra 20% off on top of the sitewide sale—up to 50% total savings! 👉 Use our Code: THEDOWNSIZED Link to purchase: https://humehealth.com//discount/THED...

To receive 20% off your Purchase of Biocare Protein Bars or Shakes, visit https://biocarenutrition.com/DOWNSIZED and enter the discount code DOWNSIZED
To Purchase LARAINE’S BIOCARE FAVORITES https://biocarenutrition.com/products... and enter the discount code DOWNSIZED to receive an additional 20%

Start your weight loss journey today! We use Mochi Health: https://app.joinmochi.com/eligibility...
Use Laraine’s code for $40 off: QIYGO8.

AMAZON GLP-1 Companion Product Store: https://www.amazon.com/shop/downsized
As an Amazon Associate, I earn from qualifying purchases.

DOWNSIZED LINKS
Website: https://thedownsized.org
Be our guest on The Downsized Dish: apply at https://thedownsized.org/downsized-dish/
Https://Thedownsized.Org/ Book The Downsized At Sea Cruise 2026: Https://Thedownsized.Org/Downsized-At...

FOR SPONSORSHIPS, BRAND DEALS & COLLABS: https://thedownsized.org/contact/
+++++++++++++++++++++++++++++++++++++++

00:00 Introduction and Major Announcement
01:53 Novo Nordisk's Announcement
02:26 Details of Cagrisema and Clinical Trials
05:49 Comparing Cagrisema with Other Treatments
07:02 Safety, Tolerability, and Real-World Use
09:20 Pricing, Access, and Market Impact
10:30 Future of Obesity Treatments
11:47 Conclusion and Call to Action

Комментарии

Информация по комментариям в разработке

Похожие видео

  • О нас
  • Контакты
  • Отказ от ответственности - Disclaimer
  • Условия использования сайта - TOS
  • Политика конфиденциальности

video2dn Copyright © 2023 - 2025

Контакты для правообладателей [email protected]